Globenewswire·2025-09-29 11:00Core Insights - Vor Bio is advancing telitacicept, a novel treatment for autoimmune diseases, with a Phase 3 study in China focusing on primary Sjögren's disease [1][3] - The clinical data will be presented at ACR Convergence 2025, highlighting the efficacy and safety of telitacicept [2] - Telitacicept has already received approvals in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis [5] Company Overview - Vor Bio is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for autoimmune diseases [3] - The company is focused on the rapid advancement of telitacicept through clinical development and commercialization [3] Product Information - Telitacicept is a dual-target fusion protein that inhibits BLyS and APRIL, which are crucial for B cell survival, thereby reducing autoreactive B cells and autoantibody production [4] - In a Phase 3 trial for generalized myasthenia gravis, telitacicept showed a placebo-adjusted improvement of 4.83 points in the MG-ADL scale at 24 weeks [4] Disease Context - Sjögren's disease is a chronic autoimmune condition characterized by overactive B cells leading to inflammation and damage to moisture-producing glands [6] - The disease is often underdiagnosed, with significant impacts on patients' quality of life and an elevated risk of lymphoma [7]